Chelation is being used for treatment of heavy metal (like lead) poisoning. This is a chemical process in which a substance is delivered intravenously (through the veins) to bind atoms of metals or minerals, and hold them tightly so that they can be eliminated from the body.
Chelation therapy is not approved by the U.S. Food and Drug Administration (USFDA) to treat heart disease. However, use of chelation therapy to treat heart disease and other health problems grew in the United States between 2002 and 2007 by nearly 68 percent to 111,000 people, according to the 2008 National Health Statistics Report.
The diabetes subgroup analysis of TACT was published in the Circulation: Cardiovascular Quality and Outcomes and presented at the American Heart Association’s Scientific Sessions 2013. TACT is a study supported by NIH’s National Center for Complementary and Alternative Medicine (NCCAM) and National Heart, Lung, and Blood Institute (NHLBI).
|Cr(edta)-2 (Photo credit: Wikipedia)|
TACT’s initial report was published in the March 27, 2013, issue of The Journal of the American Medical Association. The report showed that infusions of a form of chelation therapy using disodium ethylene diamine tetra-acetic acid (EDTA) produced a modest but statistically significant reduction in cardiovascular events in all EDTA-treated participants suffering from Diabetes Mellitus.
I have seen this form of treatment in many medical centers in Kochi, and they also claim very good outcome.
TACT was not designed to discover how or why chelation might benefit patients with diabetes. Further research may throw some light in that aspect.
The original article may be accessed here.